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OBJECTIVE — Most patients with ketosis-prone type 2 diabetes (KPD) discontinue insulin
therapy and remain in near-normoglycemic remission. The aim of this study was to determine
the effect of glucotoxicity on -cell function during remission in obese patients with KPD.
RESEARCH DESIGN AND METHODS — Age- and BMI-matched obese African Amer-
icans with a history of KPD (n  8), severe hyperglycemia but without ketosis (ketosis-resistant
type 2 diabetes, n  7), and obese control subjects (n  13) underwent intravenous infusion of
10% dextrose at a rate of 200 mg per m
2/min for 20 h. -Cell function was assessed by changes
ininsulinandC-peptideconcentrationsduringdextroseinfusionandbychangesinacuteinsulin
response (AIR) and ﬁrst-phase insulin release (FPIR) to arginine stimulation before and after
dextrose infusion.
RESULTS — ThemeanSDtimetodiscontinueinsulintherapywas7.11.7weeksinKPD
and 9.6  2.3 weeks in ketosis-resistant type 2 diabetes (NS). During a 20-h dextrose infusion,
changes in insulin, C-peptide, and the C-peptide–to–glucose ratio were similar among diabetic
andcontrolgroups.Duringdextroseinfusion,subjectswithketosis-resistanttype2diabeteshad
greaterareasunderthecurveforbloodglucosethansubjectswithKPDandcontrolsubjects(P
0.05). The AIR and FPIR to arginine stimulation as well as glucose potentiation to arginine
assessed before and after dextrose infusion were not different among the study groups.
CONCLUSIONS — Near-normoglycemia remission in obese African American patients
with KPD and ketosis-resistant type 2 diabetes is associated with a remarkable recovery in basal
and stimulated insulin secretion. At near-normoglycemia remission, patients with KPD dis-
played a pattern of insulin secretion similar to that of patients with ketosis-resistant type 2
diabetes and obese nondiabetic subjects.
Diabetes Care 33:854–860, 2010
T
he majority of obese African Ameri-
can patients with newly diagnosed
diabetes presenting with unpro-
voked diabetic ketoacidosis (DKA) dis-
play clinical and metabolic features of
type 2 diabetes during follow-up and are
able to maintain near-normoglycemic re-
mission from several months to years
without insulin or oral agents (1–7). This
variant of type 2 diabetes has been re-
ferred to in the literature as atypical dia-
betes,type1Bdiabetes,andketosis-prone
type 2 diabetes (KPD) (1,6). We and oth-
ers have reported that for more than half
of the patients with KPD, aggressive insu-
lin therapy for 10 weeks results in sig-
niﬁcant recovery of -cell function and in
improvement in insulin sensitivity to al-
low discontinuation of insulin therapy
(2,3,5,8–10).
The underlying mechanism for the
transient insulin deﬁciency leading to se-
vere hyperglycemia ketoacidosis in Afri-
canAmericanswithKPDisunknown.Itis
possiblethatsustainedhyperglycemiaper
se before the development of DKA down-
regulatesthe-cellinsulinproductionca-
pacity. The concept of “glucotoxicity” has
been put forward to explain the contribu-
tion of toxic effects of hyperglycemia on
-cell function (11). The ability of pa-
tients with KPD to be withdrawn from
insulin therapy and remain in near-
normoglycemic remission suggests hy-
perglycemia-induced transient -cell
dysfunction.However,itisnotknownex-
actly how the -cells respond to hyper-
glycemia and whether patients with KPD
during the near-normoglycemia remis-
sionphasewilldisplaydeteriorationofin-
sulin secretion after a sustained glucose
challenge. In this study, we hypothesized
that,comparedwithobesetype2diabetic
patients with hyperglycemia and obese
nondiabetic control subjects, obese Afri-
can Americans with KPD during near-
normoglycemiaremissionwillexperience
a diminished insulin response to sus-
tained elevations in blood glucose or
-cell glucotoxicity. All subjects under-
went a 20-h infusion of dextrose solution
with serial measurements of insulin, C-
peptide, and blood glucose and a sequen-
tial arginine stimulation test before and
after dextrose infusion.
RESEARCH DESIGN AND
METHODS— A group of 8 obese
(BMI 30 kg/m
2) African American pa-
tients with newly diagnosed diabetes and
a history of unprovoked DKA, 7 patients
withketosis-resistanttype2diabetes,and
13 obese nondiabetic control subjects
participated in this study. The diagnosis
of DKA was established by standard
American Diabetes Association criteria
(12).Theketosis-resistanttype2diabetes
group included patients with recently di-
agnosed diabetes with blood glucose
400 mg/dl but without metabolic aci-
dosis or ketosis. The control nondiabetic
group included obese subjects, matched
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100 mg/dl and a 2-h glucose 140
mg/dl during a (75-g) oral glucose toler-
ance test. This study was conducted at
the Clinical Research Center at Grady
Memorial Hospital (Atlanta, GA) and was
approved by the Emory University institu-
tional review board.
At presentation, diabetic patients
with DKA and hyperglycemia were
treated with a low-dose intravenous
insulin infusion protocol (12). After
resolutionofketoacidosisand/orhyper-
glycemia, patients were treated with
NPH and regular insulin twice daily at a
starting dose of 0.8 units/kg body
weight and weaned per our previously
described protocol (13).
Near-normoglycemia remission was
deﬁned as the ability to discontinue insu-
lin therapy for1 week and remaining in
good glycemic control (fasting blood glu-
cose 130 mg/dl, random blood glucose
180 mg/dl, and A1C 7%). Diabetic
subjects were admitted to the Grady Me-
morial Hospital Research Center 1
week after discontinuation of insulin
therapy. After an overnight fast, an intra-
venous catheter was placed in each fore-
arm, one for infusion and one for blood
sampling.
Twenty-hour dextrose infusion
protocol
Aninfusionof10%dextrosewith5mEq/l
of KCl was administered for 20 h at 200
mg per m
2/min. The administration of
dextrose at this rate has been shown to
result in mild-to-moderate elevation in
blood glucose levels in controlled studies
(14). During dextrose infusion, blood
sampleswerealsodrawnevery60minfor
the determination of insulin and C-
peptide and every 4 h for measurement of
free fatty acids (FFAs). The glucose infu-
sion started at 12:00 noon and continued
until 8:00 A.M. on the next morning. Sub-
jects consumed a 2,000 calories/day iso-
caloric diet (20% of calories derived from
protein, 30% from fat, and 50% from car-
bohydrate) served before the dextrose in-
fusion and at 6:00 P.M. during the glucose
infusion.
Arginine stimulation test
An arginine stimulation test enables esti-
mationsofthe-cellfunctionandtheglu-
cose potentiation of insulin secretion
(15). Two sequential arginine stimulation
tests were performed, the ﬁrst set before
and the second after completion of the
20-h dextrose infusion. Each arginine
stimulation test set was performed at
baseline and after a 45-min infusion of
10% dextrose at 200 mg per m
2/min. A
maximally stimulatory dose of 10% argi-
nine (5 g) was injected as a bolus over a
period of 30 s, and blood samples were
drawn at 30, 0, 2, 3, 4, 5, 7, 15, and 30
min for measurement of glucose and in-
sulin levels.
Calculations
Acute insulin response (AIR) to arginine
was deﬁned as the difference between
basal (30 and 0 min) and the mean in-
sulinvaluesat2,3,4,and5minaftereach
arginine pulse at fasting glucose (AIR1)a s
wellasafter45minofdextroseinfusionat
200 mg per m
2/min (AIR2). First-phase
insulin release (FPIR) was calculated as
thesumoftheinsulinlevelsat2,3,5,and
7 min after arginine infusion. Insulin re-
sistance was estimated by homeostasis
model assessment of insulin resistance
(HOMA-IR) derived from fasting plasma
glucose and insulin (HOMA-IR  fasting
insulin[milliunitsperliter]fastingglu-
cose [millimoles per liter]/22.5). We also
estimated insulin sensitivity for the level
of insulin secretion (HOMA-IR/FPIR),
which is predictive of progression to
-cell failure and to type 1 diabetes (16).
Laboratory methods
Plasma glucose was measured using the
glucoseoxidasemethod.Levelsofinsulin,
C-peptide, and FFAs were measured in
plasma using solid-phase, two-site se-
quential chemiluminescent immunomet-
ric assays on the DPC Immulite analyzer
(Diagnostic Products, Los Angeles, CA).
The instrument calibrations for the as-
says were performed as recommended
by the manufacturer and were within
the speciﬁcations.
Statistical analysis
All data in the text and tables are ex-
pressed as means  SD, and the data in
ﬁgures are expressed as means  SEM.
Comparisons among the nondiabetic
control group, KPD group, and obese di-
abetic group with hyperglycemia were
conducted using a nonparametric
Kruskal-Wallis test for continuous vari-
ablesandaFisherexacttestforcategorical
variables. Further analysis for statistical
differences between groups was per-
formed by ANOVA. With glucose infu-
sion data, repeated-measures analyses
wereperformedtoassessthegroupdiffer-
encesimultaneouslywiththechangeover
time in blood glucose, insulin, and C-
peptide–to–glucose ratio, adopting an
AIR1 within-subjects correlation struc-
ture. Statistical signiﬁcance was deﬁned
as P  0.05. Statistical analysis was per-
formed using SAS (version 9.2; SAS Insti-
tute, Cary, NC).
RESULTS
Patient characteristics
The clinical characteristics of patients
with KPD, patients with ketosis-resistant
diabetes, and nondiabetic control sub-
jects are shown in Table 1. Age and BMI
were similar among study groups. Most
patients with KPD and ketosis-resistant
type2diabeteshadastrongfamilyhistory
ofdiabetes,hadnewlydiagnoseddiabetes
at presentation, and were predominantly
men. On admission, the patients with
KPD had a mean blood glucose level of
712  342 mg/dl and had metabolic aci-
dosis. The ketosis-resistant diabetic pa-
tients with hyperglycemia had an
admission blood glucose of 492  163
mg/dlbutlackedthefeaturesofmetabolic
acidosis (Table 1). The mean time to
achieve remission and insulin discontin-
uation was similar in obese patients with
KPD and ketosis-resistant diabetes (Table
1). At remission, both groups of patients
with diabetes had similar glucose and
A1C levels.
Metabolic studies and AIR to
arginine stimulation
The results of fasting glucose and plasma
insulin levels and arginine stimulation
tests are shown in Table 2. At near-
normoglycemic remission, plasma con-
centrations of fasting blood glucose,
insulin, C-peptide, and HOMA-IR values
were not signiﬁcantly different between
patients with KPD and obese nondiabetic
control subjects (NS). However, patients
with ketosis-resistant diabetes had higher
fasting glucose and HOMA-IR compared
with control subjects (P  0.05). Fasting
FFA levels were not signiﬁcantly different
between diabetic patients at remission
and control subjects (Table 2).
AIR and FPIR to arginine stimulation
was not signiﬁcantly different in patients
with KPD and ketosis-resistant type 2 di-
abetes compared with those in control
subjects both before and after a 20-h dex-
trose infusion (Table 2, Fig. 1). Similarly,
the FPIR adjusted for insulin sensitivity
(HOMAIR–to–FPIRratio)wassimilarbe-
tween groups before and after a glucose
load (Table 2).
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glucose ratio, and FFAs during 20-h
dextrose infusion
Dextrose infusion at a rate of 200 mg per
m
2/min (25 g glucose/h or 250 ml/h of
10% dextrose solution for a 100-kg per-
son) resulted in mild elevation of blood
glucosefrombaselineinbothdiabeticand
control subjects (Fig. 2A). Repeated-
measures analyses showed that, during
theinfusion,bloodglucoseconcentration
signiﬁcantly increased over time from
baseline in all groups (P  0.05). How-
ever,thepatientswithKPDhadonlymild
blood glucose elevation during a 20-h
dextrose infusion, which was similar to
that in the control group; in contrast, the
patients with ketosis-resistant diabetes
had greater blood glucose elevation dur-
ing dextrose infusion compared with that
in the two other groups (P  0.006). The
area under the curve for glucose levels
was similar between the control and KPD
groups but was signiﬁcantly greater in
obese subjects with ketosis-resistant type
2 diabetes at 2,469  254, 2,804  344,
and 3,607  254 mg/dl per 20 h, respec-
tively (P  0.002).
All subjects experienced statistically
signiﬁcant increases in insulin concentra-
tion and insulin secretion as assessed by
the C-peptide–to–glucose ratio during
the20-hglucoseinfusion(Fig.2BandC).
However, neither subjects with KPD nor
those with ketosis-resistant diabetes had
signiﬁcant changes in insulin and the C-
peptide–to–glucose ratio compared with
the control group assessed at most time
points (Fig. 2B and C) or by the area un-
der the curve (NS).
In nondiabetic control patients,
dextrose infusion was associated with a
signiﬁcant decrease in FFA levels. Prein-
fusion FFA levels (113  21 	mol/l)
markedly declined during dextrose infu-
sion to 63  8, 70  7, 56  2, and 42 
8 	mol/l at 8, 12, 16, and 20 h, respec-
tively (P  0.05). In contrast, in the
groupswithKPDandketosis-resistantdi-
abetes, levels of FFAs did not substan-
tially change from the baseline value
throughout the 20-h dextrose infusion
(NS).
CONCLUSIONS — The two major
ﬁndings in our study are the remarkable
recovery of basal and stimulated insulin
secretionduringthenear-normoglycemic
remission in patients with newly diag-
nosed KPD, and the lack of -cell failure
(glucotoxicity) after a short-term intrave-
nous dextrose infusion. Patients with
KPD at near-normoglycemia remission
showed a magnitude of insulin secretion
in response to a 20-h dextrose infusion
and AIR to arginine stimulation similar to
the response observed in nondiabetic
control and ketosis-resistant type 2 dia-
betic subjects.
A large body of evidence indicates
thatthemajorityofpatientswithKPDdis-
play clinical, metabolic, and immunolog-
ical features of type 2 diabetes, are able to
discontinue insulin therapy in 2–3
months, and remain in normoglycemic
remission for months to several years (1–
3,5,6). Previous work demonstrated that
atpresentationpatientswithKPDhaveno
insulin response to glucose; however,
during remission such patients are able to
produce insulin in response to intrave-
nous glucose similar to nondiabetic sub-
jects (5,7). In addition, the resolution of
hyperglycemia after 10–12 weeks of in-
Table1—ClinicalfeaturesofcontrolsubjectsandsubjectswithKPDandketosis-resistanttype
2 diabetes presenting with hyperglycemia
Control KPD
Ketosis-resistant
diabetes
n 13 8 7
Age (years) 40.0  9.3 42.8  10.6 49.7  8.1
Sex (male/female) 1/12 6/2 5/2
Newly diagnosed diabetes (%) — 100 100
Family history of diabetes (%) 77 88 100
BMI (kg/m
2) 35.5  5.0 38.6  4.9 37.2  5.6
Weight (kg) 96.3  13.9 120.3  23.3 110.2  19.7
Body surface area (m
2) 2.1  0.2 2.4  0.3 2.3  0.3
Blood glucose at presentation (mg/dl) 90  9 712  342* 492  163*
A1C at presentation (%) — 12.1  3.6 13.0  2.3
Bicarbonate (mmol/l) — 14  4† 24  3
pH — 7.20  0.22 7.37  0.04
Anion gap (mmol/l) — 24.8  7.2† 12.8  5.4
-Hydroxybutyrate (mmol/l) — 6.3  3.0† 1.02  0.4
Time to remission (weeks) — 7.1  1.7 9.6  2.3
A1C at remission (%) — 5.9  0.3 6.4  1.1
Blood glucose at remission (mg/dl) — 95  9 104  18
Data are means  SD or %. *P  0.01 vs. control. †P  0.05 vs. ketosis-resistant diabetes.
Table 2—Metabolic characteristics of nondiabetic control subjects, subjects with KPD, and
subjects with ketosis-resistant type 2 diabetes at near-normoglycemia remission
Control KPD
Ketosis-resistant
diabetes
n 13 8 7
Fasting glucose (mg/dl) 88  29 5  3 104  8*
Fasting insulin (	U/ml) 10.7  1.7 16.0  4.5 15.8  3.0
Fasting C-peptide (ng/ml) 2.3  0.6 2.7  0.6 2.7  0.6
HOMA-IR 2.3  0.4 3.6  1.0 4.0  0.8*
FFAs (	mol/l) 113  21 120  35 117  29
AIR and FPIR to arginine stimulation and HOMA-IR–to–FPIR ratio before and after glucose
infusion (200 mg per m
2/min) for 20 h
Before 20-h glucose infusion
Preinfusion AIR1 (	U/ml) 31  63 9  14 52  23
FPIR (	U/ml) 197  33 264  80 339  221
HOMA-IR–to–FPIR ratio 0.014  0.003 0.015  0.003 0.013  0.002
After 20-h glucose infusion
Postinfusion AIR1 (	U/ml) 40  53 4  13 62  27
FPIR (	U/ml) 299  30 359  42 381  147
HOMA-IR–to–FPIR ratio 0.010  0.002 0.012  0.005 0.013  0.005
Data are means  SE. *P  0.05 vs. control.
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peripheral insulin sensitivity. Hence,
these studies suggested that patients with
KPD who achieved near-normoglycemic
remissionmaynothaveirreversible-cell
damage; rather, these patients who
present with a hyperglycemic crisis
have only transient functional abnor-
malities of insulin secretion or -cell
“desensitization.”
Evidence has shown that the contin-
uous exposure of -cells to an elevated
glucose concentration impairs insulin
production and, if high glucose persists
long enough, leads to irreversible damage
of-cells,aconceptcalled“glucotoxicity”
(11). Although most evidence supporting
thephenomenonof-celldamageisborn
from in vitro and in vivo studies (17), the
concept of pancreatic glucotoxicity is
thought to underlie loss of insulin pro-
duction in the progression of type 2 dia-
betes (18,19). Intensive insulin treatment
has been shown to provide long-term
-cellbeneﬁtsnotonlyinKPDbutalsoin
the setting of initial therapy for type 2 di-
abetes. Weng et al. (20) recently reported
that 1 week of intensive insulin adminis-
tration in patients with newly diagnosed
type 2 diabetes resulted in remission of
diabetes in half of the patients after 1 year
of follow-up. In our study, we tested
whether prolonged glucose exposure in
patients with KPD at remission would re-
sult in -cell dysfunction. We found that
the patients with KPD experience in-
creases in insulin and C-peptide levels
and in the C-peptide–to–glucose ratio
similar to those in control subjects during
the 20-h dextrose infusion (Fig. 2). In ad-
dition, control subjects and patients with
KPD had a comparable area under curve
for glucose, suggesting that insulin-
mediated glucose disposal in patients
with KPD at remission is similar to that
observed in nondiabetic obese subjects.
In an attempt to understand the in
vivophenomenonofpancreaticglucotox-
icity, -cell responsiveness to prolonged
dextrose infusion was studied previously
in healthy subjects. In lean or overweight
nondiabetic humans, the infusion of dex-
trose ranging up to 68 h and resulting in
sustained hyperglycemia at levels be-
tween 108 and 170 mg/dl did not cause
suppression of insulin secretion (14,
21,22).Also,exvivoincubationofhuman
Figure1—Argininestimulationtestsperformedbefore(A)andafter(B)a20-hdextroseinfusionincontrolsubjects,subjectswithKPD,andsubjects
with ketosis-resistant diabetes (DM). A maximally stimulatory dose of 10% arginine (5 g) was injected at baseline plasma glucose and after an
infusion of 10% dextrose at 200 mg per m
2/min for 45 min. Data are means  SE. BG, blood glucose in milligrams per deciliter.
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mg/dl revealed no signs of glucotoxicity
(23). Boden et al. (21), however, demon-
strated that, in overweight subjects, insu-
lin secretion did not fall until 68 h of
dextroseinfusionthatwasassociatedwith
abloodglucoselevelof227mg/dl.Wedo
not know whether exposure to higher
glucose concentrations would result in
-cell failure in patients with KPD.
The hyperglycemic potentiating ef-
fectoftheinsulinresponsetoarginineisa
sensitive indicator of -cell secretory ca-
pacity (18,24). The patients with KPD
demonstrated an appropriate glucose-
Figure2—Changesinbloodglucose(A),insulin(B),andtheC-peptide–to–glucoseratio(C)duringa20-hglucoseinfusionas10%dextroseat200
mgperm
2/minincontrolsubjects,subjectswithKPD,andsubjectswithketosis-resistantdiabetes(DM)1weekafterachievingnear-normoglycemic
remission. Data are means  SE.
-Cell function in KPD
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injection (Table 2). We did not observe
increasesininsulinsecretioninallgroups
studiedinresponsetothesecondarginine
infusion after a 20-h dextrose infusion
(Table 2, Fig. 1); however, we were not
able to achieve a similar degree of hyper-
glycemiaduringthesecondarginineinfu-
sion. The ability of patients with KPD to
appropriatelyincreaseinsulinsecretionto
prolonged glucose infusion and during
repeated arginine stimulation indicated a
remarkable recovery of insulin secretion
during near-normoglycemia remission.
These results suggest that the patients
with KPD during remission have signif-
icant -cell reserve to counteract the
deleterious effect of short-term mild
hyperglycemia.
Our study also indicates that patients
with ketosis-resistant type 2 diabetes are
more insulin resistant than the patients
with KPD. The surrogate marker of insu-
lin resistance, HOMA-IR, was higher in
the patients with ketosis-resistant diabe-
tes (Table 2), and blood glucose levels
were also higher during a 20-h dextrose
infusion,suggestinglowerglucoseutiliza-
tion than that in control subjects and pa-
tients with KPD (Fig. 2). These ﬁndings
are in accord with previous work by
Garvey et al. (25). These authors demon-
strated that in patients with poorly con-
trolled type 2 diabetes, intensive insulin
therapy for 3 weeks results in improve-
ment in -cell function; however, despite
improved glycemic control, patients will
remain insulin-resistant. Increased pe-
ripheralinsulinresistanceinpatientswith
KPD and ketosis-resistant diabetes com-
paredwithhealthycontrolsubjectsisalso
suggested by the lack of suppression of
FFA during a 20-h dextrose infusion.
We acknowledge the following limi-
tations in this study. We anticipated that
the infusion of dextrose at 200 mg per
m
2/min for 20 h (10% dextrose at 250–
300 ml/h) would result in signiﬁcant hy-
perglycemia in patients with a recent
history of DKA and/or severe hyperglyce-
mia.However,weobservedonlymildhy-
perglycemia that may not have been
sufﬁcient to impair -cell responses. A
higher dextrose infusion rate resulting in
a higher glucose concentration may be
needed to achieve signiﬁcant glucotoxic-
ity (21). It is also feasible that the devel-
opment of glucotoxicity requires the
presence of elevated FFAs. In addition to
inhibiting insulin action, recent evidence
indicates that FFAs have an important
role in regulation of -cell function (11).
Finally, our study included only African
Americans,sotheeffectofprolongeddex-
trose infusion in patients with KPD from
different ethnic populations needs to be
determined in future studies.
In summary, our studies demon-
strate that, in patients with KPD, near-
normoglycemia remission is associated
with a remarkable recovery in insulin se-
cretion. Despite a recent history of severe
hyperglycemia and ketoacidosis, patients
with KPD in remission had basal and
stimulated insulin secretion similar to
those in obese healthy control subjects
sufﬁcient to prevent hyperglycemia dur-
ing dextrose infusion.
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